WO1991002091A1 - Procede d'identification d'herpes virus et oligonucleotides utilises dans le procede - Google Patents

Procede d'identification d'herpes virus et oligonucleotides utilises dans le procede Download PDF

Info

Publication number
WO1991002091A1
WO1991002091A1 PCT/US1990/004507 US9004507W WO9102091A1 WO 1991002091 A1 WO1991002091 A1 WO 1991002091A1 US 9004507 W US9004507 W US 9004507W WO 9102091 A1 WO9102091 A1 WO 9102091A1
Authority
WO
WIPO (PCT)
Prior art keywords
herpesvirus
sequence
guanosine
cytosine
adenosine
Prior art date
Application number
PCT/US1990/004507
Other languages
English (en)
Inventor
Anne H. Rowley
Steven M. Wolinsky
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of WO1991002091A1 publication Critical patent/WO1991002091A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster

Definitions

  • the field of this invention is the detection and identification of viruses that are members of the Herpesvirus family. More particularly, the invention is concerned with the identification of DNA viruses, par ⁇ ticularly those of the herpesvirus family by detection of nucleic acid sequences that are distinctive for the individual members of the family.
  • Detection of viral DNA in specimens compris ⁇ ing body fluids or tissues can be difficult because of the small quantity of viral DNA present in the specimen and/or because of the presence of other interfering materials, including DNA from a different source.
  • PCR polymerase chain reaction
  • pairs of oligonucleotide primers may be employed as described in United States Patent 4,683,202.
  • the primers are designed to hybridize with sequences that flank the target DNA.
  • the amplified target sequence is detected by a hybridizing, virus-specific probe.
  • this analytical procedure has been used for direct detection of HIV-1 (AIDS virus) , as described by Ou, et al., Science. 238, 295-297 (January 15, 1988) .
  • the amplification cycles are facilitated by using a polymerase which is thermally stable in incuba ⁇ tions up to 95 ⁇ C, as described by Saiki, et al. , Science. 239, 487-491 (January 29, 1988).
  • the DNA polymerase genes of several herpes- viruses have been sequenced, and the corresponding a ino acid sequences of the catalytic polypeptide inferential- ly determined.
  • the available sequence information has been summarized from data retrieved from DNA sequences databanks (i.e., Genbank) and previously published reports: Gibbs, et al., Proc. Natl. Acad. Sci. USA. 82:7969-7973 (December 1985) , and Earl, et al., Proc. Natl. Acad. Sci. USA, 83:3659-63 (June 1986).
  • the herpesviruses compared included Herpes simplex virus, cytomegalovirus, and Epstein-Barr virus.
  • the comparative table on page 42 of Wong, et al. indicates certain regions that are highly conserved between different members of the herpesvirus family while other regions are more variable.
  • This invention provides a method for iden ⁇ tifying the DNA polymerase gene from at least four different viruses that are members of the herpesvirus family.
  • the method employs primer-directed enzymatic amplification of the hybridized complementary nucleo- tide segments of the herpesvirus polymerase genes. More specifically, the method utilizes dual primers for ampli- fication and detection of significant segments of Herpes simplex type 1, Herpes simplex type 2, Epstein-Barr virus, and cytomegalovirus. For specific identification of the amplified sequences, a series of specific oligonucleotide probes are provided. These probes hybridize only with the sequence of Herpes simplex types 1 and 2, Epstein-Barr virus, or cyto episcopo- virus. Thus, when the clinician has indications suggesting a particular herpesvirus infection, the tentative diagnosis can be confirmed, or, if it fails to-be confirmed, others of the three probes can be used to identify one of the other species of herpesvirus.
  • Herpesvirus infections • can be of critical importance in immunosuppressed or i - munocompromised patients, such as transplant patients or AIDS patients.
  • the method will also permit more rapid and reliable diagnosis of congenital cytomegalovirus in ⁇ fections and herpes encephalitis. Moreover, many more uses of the method of this invention in medical practice are anticipated.
  • the method of this invention utilizes syn ⁇ thetic oligonucleotide sequences as primers and probes.
  • These sequences can be prepared by well-known chemical procedures, and commercially available automatic DNA synthesizers can be used.
  • the required se ⁇ quences can be prepared by the synthesis method described by Beaucage, et al.. Tetrahedron Letters. 22:1859-1962 (1981) .
  • Another usable method for synthesizing oligo- nucleotides on a solid support is described in U.S. Patent 4,458,066.
  • Automated DNA synthesizer apparatus can be used, such as the DNA synthesizers sold by Applied Biosystems.
  • Oligonucleotide sequences required for prac ⁇ ticing the method of this invention comprise two primer sequences and three probe sequences or inversions of the probe sequences. These single strand oligonucleotides are represented by the standard letter abbreviations in which the nucleotides are designated as follows: A for adenosine, T for thymidine, G for guanosine, and C cytosine. These strands are represented in a standard 5' prime to 3' prime orientation.
  • oligonucleotides are the in ⁇ verted complementary nucleotide sequences for the type- specific probes. Similar sequence variation does not exist for the generic amplification oligonucleotide primer pair. Polarity is in the standard 5 1 to 3 1 orientation.
  • Pri er sequences 1 and 2 can be employed in the generic amplification of four herpesviruses; namely, Herpes simplex types 1 and 2, Epstein-Barr virus, and cytomegalovirus. They are designed to hybridize with highly conserved regions of the polymerase genes of these viruses. Primers 1 and 2 target to Regions I and II as shown by Wong, et al. (1988) , cited above. These primers are capable of effectively hybridizing and serving as primers for the thermostable DNA polymerase used in the amplification process for all of the herpesvirus species detectable by the method of this invention.
  • Probes are designed to be species- specific with respect to different segments of the polymerase DNA flanked by the primers. This specificity was not predictable and had to be experimentally con ⁇ firmed. Probes (a) or (a 1 ) hybridize specifically to the amplified polymerase segment of Herpes simplex types 1 and 2, while not hybridizing to the amplified segments of either of the other two herpesviruses. Similar specificity applies with respect to probes (b) and (b') for Epstein-Barr virus, and probes (c) and (c 1 ) for cytomegalovirus. None of these oligonucleotide probe sequences cross-hybridized with the human DNA polymerase gene.
  • probes (a) , (a 1 ) , (b) , (b 1 ) , (c) , and (c 1 ) are targeted to hybridize with sequences in Region III.
  • the targeted sequences in Region III provide sufficient variations to assure the desired selective hybridizing. This is important since partial correspondence of DNA sequences can lead to non-selective hybridization which could interfere with specificity.
  • primers and probes of this invention are preferably used in accordance with the general procedure described in United States Patent 4,683,202.
  • the specimen to be tested for herpesvirus identification may be any body fluid, such as blood, serum, urine, feces, spinal fluid, etc., and the sample may be derived from body tissues. After removing solid debris from the sample, it is prepared for polymerase amplification by adding an excess of the four deoxyribo- nucleotide triphosphates for adenosine 5' triphosphate (A) , thymidine 5• triphosphate (T) , guanosine 5' triphosphate cystosine (Gg) and cytosine 5 1 triphosphate (C) .
  • a buffer may also preferably added, such as a Tris acetate buffer.
  • Other additives may include sodium acetate, magnesium acetate, and dithiothreitol.
  • the test specimen may be heated to an effect ⁇ ive melting temperature. For example, heating to temperatures of about 95 to 100°C. Heating for 1 to 2 minutes at 95"C is usually effective for denaturation. Following heating, the solution may be brought back to a room temperature (viz. 20 to 25 ⁇ C) .
  • the polymerase enzyme for the amplification reaction is then added. As described in United States Patent 4,683,202, this may be the Klenow fragment jS. coli DNA polymerase, or T 4 DNA polymerase.
  • a thermal ⁇ ly stable polymerase is employed, such as isolated from Thermus aquaticus DNA polymerase as described by Saiki, et al.
  • primers (1) and (2) are added in large molar excess over the viral polymerase target DNA expected to be present. For example, from 50 to 100 picomoles (P oles) of each primer may be added per each 100 microliters (1) of test solution.
  • Hybridization of the oligonucleotide primers with the viral polymerase can be carried out after thermal denaturation of the target DNA at various temperatures, such as 37-68°C. A preferred temperature is about 55°C.
  • the primers rapidly hybridize with the target DNA sequences, usually requiring less than two minutes.
  • the Taq polymerase catalyzed primer extension using the target DNA sequence as a template will also occur rapidly, usually requiring less than three minutes.
  • the amplified segments which are in double strand form, are denatured, such as by further heating at a tempera ⁇ ture of around 95°C for one to two minutes.
  • the solution may then be heated to an effective temperature for target DNA denaturation and further oligonucleotide primer annealing and Taq polymerase primer extension, such as previously described, and, if needed, additional polymerase en-zyme is added.
  • the cycles of thermal denaturation, primer annealing or hybridization, and Taq polymerase-directed primer extension to obtain further amplification are repeated for as long as required to facilitate detection of the viral DNA. Usually, from about 30 to 40 cycles are sufficient for effective detection.
  • the test sample is again at ordinary room temper ⁇ ature (20-25 ⁇ C) , and one of the probes (a, a', b, b', c, c 1 ) is added to the solution.
  • the probes may be tagged such as with a radioactive label, a biotinylated label, or a fluorescent label. It may be convenient to attach the label to one of the end nucleotides of the probe. For routine clinical analysis, non-radioactively labeled probes may be preferred.
  • Biotin-containing DNA probes can be detected by chro agenic enzymes linked to Avidin, or Biotin-specific antibodies.
  • an aliquot of the sample is examined to confirm hybridization or non-hybridiza ⁇ tion.
  • the aliquot may be subjected to polyacrylamide gel electrophoresis.
  • the other probes can be used in a similar way to confirm or eliminate detection of each of the other herpes*- • viruses. For example, it may be found necessary to use a sequence of two to three of the probes, thereby either identifying one of the four herpesviruses, or eliminating all four as not present in the sample.
  • the method of this invention is further illustrated by the following procedural examples:
  • Heparinized peripheral blood is first sub ⁇ jected to osmotic red blood cell (RBC) lysis.
  • the re ⁇ maining white blood cells, a buffy coat preparation from peripheral blood, or white blood cells separated by flow cytometry may then be lysed in 50 mM KC1, lOmM Tris HC1 (pH 8.3) , 2.5 mM MgCl 2 , 0.45% NP40, -0.45% Tween 20, and 30 mg proteinase K for 1 hour at 55°C.
  • the DNA is obtained by phenol/chloroform extraction and ethanol precipitation, and an aliquot is used as the test sample for the method of this invention.
  • Urine samples, saliva samples, serum samples, cerebrospinal fluid, and other body fluids may be sub ⁇ jected first to ultracentrifugation at 37,000 rpm for 1 hour, followed by lysis and DNA purification as above. Direct amplification of aliquots following lysis but without further DNA purification may be feasible.
  • cerebrospinal fluid or other body fluids may be subjected to phenol/chloroform extraction and DNA precip ⁇ itation without ultracentrifugation or lysis in order to detect free DNA. Direct amplification of cerebrospinal fluid and other body fluids without any preparation may also be feasible.
  • a standard PCR reaction mix can contain 50 p oles of each oligonucleotide primer, 200 M of each of the four dNTPs, 50 mM KC1, 2.5 mM MgCl 2 , 20 g gelatin, and 2.5 units of Thermus aquaticus (Taq) thermostable DNA polymerase. To this mix is added 25 ul of the sample to be amplified in a 100 ul final reaction volume. To en ⁇ sure that the sample contains DNA which is of the quality to be amplified, enzymatic amplification can first be performed on the sample using oligonucleotide primers (GH26 and GH27) , which were derived from highly conserved sequences in the HLA DQ alpha locus of human DNA.
  • oligonucleotide primers GH26 and GH27
  • a 30-40 repeated cycles of target DNA denaturation, primer annealing, and Taq poly erase-catalyzed template extension results in an exponential accumulation of a 242 base pair fragment.
  • Suitable denaturation and annealing temperatures are, respectively, 95 and 55 ⁇ C.
  • An aliquot of the amplified product is resolved by agarose gel electrophoresis and visualized by ethidium bromide staining. The migration of amplified DNA is compared with a known molecular weight standard. Sample aliquots which show an amplified HLA DQ alpha product are then amplified using oligonucleotide primers derived from the DNA polymerase gene of the herpesviruses.
  • 15 1 of amplified product is analyzed by oligomer hybridization and/or dot blot hybridization.
  • OLIGONUCLEOTIDE HYBRIDIZATION Hybridization is performed in solution by adding 15 ul of amplified product to 0.02 p oles of radioactively labelled oligonucleotide probe in 50 mM NaCl and 4 mM EDTA. The reaction mix is heated at 95 ⁇ C for five minutes to denature the double-stranded DNA, and then incubated at 55°C for 15 minutes so that hybridiza ⁇ tion to the radioactively labelled probe will occur. One half of the reaction volume is then resolved by electro ⁇ phoresis on a 6% polyacrylamide gel. The probe: ampli- fied product heteroduplex is visualized by autoradiogra- phy following exposure to Kodak XAR film with intensify ⁇ ing screens for 12 hours at -70°C.
  • DOT-BLOT HYBRIDIZATION Dot blot hybridization allows for hybridiza ⁇ tion on a solid support, and the stringency of hybridiz ⁇ ation and washing procedures may be altered to minimize non-specific hybridization but allow for slight base pair mismatches that would be necessary for the detection of new, closely related viruses.
  • 10 ul of amplified product is mixed with 0.4 m NaOH and 25 mM EDTA in order to denature double-stranded DNA, and the resulting solution is applied to a Gentran nylon membrane presoaked in 0.4 M Tris HC1 (pH 7.5) . After the DNA is applied, the membrane is washed with 2x SSC and exposed to ultraviolet light for 5 minutes.
  • the membrane is then presoaked in 2x SSC, 10X Denhardt's solution, 0.5% SDS, and incubated at 68°C for 45 minutes.
  • One mg of salmon sperm DNA and 0.4 pmoles of 32 P end-labelled oligonu ⁇ cleotide probe are added, and the membrane is incubated for an additional 3 hours at 55°C.
  • the membrane is then washed twice with 2X SSC and 0.1% SDS at 55°C for 10 minutes.
  • a final high stringency wash with 0.2X SSC and 0.1% SDS preheated to 55°C is performed. Higher or lower temperatures and salt concentrations may be used to vary the stringency of the hybridization and washing proceed ⁇ ures.
  • CLINICAL USES OF PRIMERS AND PROBES The presence has been demonstrated of cytomegalovirus (CMV) DNA in blood and urine of infected individuals, Herpes simplex DNA in cerebrospinal fluid from patients with herpes encephalitis, and Epstein-Barr (EBV) DNA from saliva of patients with acute infectious mononucleosis.
  • CMV cytomegalovirus
  • Herpes simplex DNA in cerebrospinal fluid from patients with herpes encephalitis Herpes simplex DNA in cerebrospinal fluid from patients with herpes encephalitis
  • Epstein-Barr (EBV) DNA DNA from saliva of patients with acute infectious mononucleosis.
  • Preliminary studies indicate that the method of this invention is sensitive enough to detect latent, or nonreplicative infection in such body fluids. It is also expected that the method can be extended to detection of mRNA species from the DNA polymerase gene, thereby indicating active infection.
  • the primers and probes of this invention can be useful in identifying the presence of a specific herpesvirus in clinical samples.
  • EBV and CMV may cause similar symptoms so that amplification with the primers (l) and (2) followed by hybridization with the probes (b) or (b 1 ) and (c) or (c 1 ) will provide a rapid method for distinguishing which of the two viruses is present.
  • a screen for all four herpesviruses may also be useful in the specific diagnosis of viral encephalitis and meningoencephalitis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Procédé d'identification d'herpès virus. Les oligonucléotides décrits, utilisés dans le procédé comprennent des doubles amorces ainsi que des sondes d'hybridation sélectives permettant une amplification de la réaction en chaîne de la polymérase ainsi que l'identification ultérieure des virus. On peut distinguer au moins quatre virus différents de la famille de l'herpès virus comprenant l'Herpès simplex de type 1, l'Herpès simplex de type 2, le virus d'Epstein-Barr, et le cytomégalovirus.
PCT/US1990/004507 1989-08-10 1990-08-09 Procede d'identification d'herpes virus et oligonucleotides utilises dans le procede WO1991002091A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39220989A 1989-08-10 1989-08-10
US392,209 1989-08-10

Publications (1)

Publication Number Publication Date
WO1991002091A1 true WO1991002091A1 (fr) 1991-02-21

Family

ID=23549723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004507 WO1991002091A1 (fr) 1989-08-10 1990-08-09 Procede d'identification d'herpes virus et oligonucleotides utilises dans le procede

Country Status (2)

Country Link
AU (1) AU6164890A (fr)
WO (1) WO1991002091A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014846A1 (fr) * 1991-02-25 1992-09-03 Iatron Laboratories, Inc. Procede pour detecter le virus de l'herpes avec specificite selon le type
EP0574048A2 (fr) * 1992-03-13 1993-12-15 Akzo Nobel N.V. Peptides et séquences d'acide nucléique associés au virus Epstein Barr
WO1993025707A2 (fr) * 1992-06-05 1993-12-23 Instituto De Salud Carlos Iii Procedes d'amplification de genome et melanges d'oligonucleotides initiateurs pour la detection et l'identification de sequences genomiques apparentees
EP0625214A1 (fr) * 1991-12-23 1994-11-23 Chiron Corporation Sondes de cmv utilisees dans des methodes d'hybridation en sandwich a phase en solution
EP0630973A2 (fr) * 1993-05-14 1994-12-28 Johnson & Johnson Clinical Diagnostics, Inc. Compositions de diagnostic, éléments, procédés et kits pour tests d'amplification et de détection de deux ou plusieurs ADN's utilisant des amorces à températures de fusion-adaptés
WO1995003415A2 (fr) * 1993-07-23 1995-02-02 Hans Joachim Wolf Sequences d'adn du virus epstein-barr codant un antigene de capside viral utilisable en diagnostic, clones d'expression derives par amplification pcr, et utilisation de cet antigene recombine dans des tests diagnostiques
WO1996025909A2 (fr) * 1995-02-17 1996-08-29 Instituto De Salud Carlos Iii Procedes d'amplification de genomes et melanges d'oligonucleotides initiateurs pour la detection et l'identification d'agents infectieux apparentes
US6008327A (en) * 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
EP1659187A1 (fr) * 2004-11-18 2006-05-24 bioMerieux B.V. Séquences d'acides nucléiques qui peuvent être utilisées comme amorces et sondes dans l'amplification et la détection de l'ADN de HSV et méthodes pour l'amplification et la détection de l'ADN de HSV en utilisant une amplification basée sur la transcription

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229701A2 (fr) * 1986-01-10 1987-07-22 F. Hoffmann-La Roche Ag Détection des virus par amplification et hybridation
EP0269445A2 (fr) * 1986-11-26 1988-06-01 Cetus Oncology Corporation Procédé de détection des virus HTLVI et HTLVII par hybridation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229701A2 (fr) * 1986-01-10 1987-07-22 F. Hoffmann-La Roche Ag Détection des virus par amplification et hybridation
EP0269445A2 (fr) * 1986-11-26 1988-06-01 Cetus Oncology Corporation Procédé de détection des virus HTLVI et HTLVII par hybridation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EMBO JOURNAL, Volume 7, No. 1, issued 1988, WONG et al., "Human DNA Polymerase & Gene Expression is Cell Prolifiration Dependent and its Primary Structure is Similar to Both Prokaryotic and Eukaryotic Replicative DNA Polymerases", pages 37-47. *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014846A1 (fr) * 1991-02-25 1992-09-03 Iatron Laboratories, Inc. Procede pour detecter le virus de l'herpes avec specificite selon le type
EP0625214A1 (fr) * 1991-12-23 1994-11-23 Chiron Corporation Sondes de cmv utilisees dans des methodes d'hybridation en sandwich a phase en solution
US5407795A (en) * 1991-12-23 1995-04-18 Chiron Corporation CMV probes for use in solution phase sandwich
EP0625214A4 (en) * 1991-12-23 1997-07-16 Chiron Corp Cmv probes for use in solution phase sandwich hybridization assays.
US5424398A (en) * 1992-03-13 1995-06-13 Akzo N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
EP0574048A2 (fr) * 1992-03-13 1993-12-15 Akzo Nobel N.V. Peptides et séquences d'acide nucléique associés au virus Epstein Barr
EP0574048A3 (fr) * 1992-03-13 1994-03-02 Akzo Nv
EP1225226A1 (fr) * 1992-03-13 2002-07-24 Organon Teknika B.V. Peptides et séquences d'acide nucléique associés au virus Epstein Barr
US6008327A (en) * 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
WO1993025707A2 (fr) * 1992-06-05 1993-12-23 Instituto De Salud Carlos Iii Procedes d'amplification de genome et melanges d'oligonucleotides initiateurs pour la detection et l'identification de sequences genomiques apparentees
WO1993025707A3 (fr) * 1992-06-05 1994-02-17 Inst De Salud Carlos Iii Procedes d'amplification de genome et melanges d'oligonucleotides initiateurs pour la detection et l'identification de sequences genomiques apparentees
EP0630973A2 (fr) * 1993-05-14 1994-12-28 Johnson & Johnson Clinical Diagnostics, Inc. Compositions de diagnostic, éléments, procédés et kits pour tests d'amplification et de détection de deux ou plusieurs ADN's utilisant des amorces à températures de fusion-adaptés
EP0630973A3 (fr) * 1993-05-14 1995-04-26 Eastman Kodak Co Compositions de diagnostic, éléments, procédés et kits pour tests d'amplification et de détection de deux ou plusieurs ADN's utilisant des amorces à températures de fusion-adaptés.
US5741656A (en) * 1993-07-23 1998-04-21 Hans Joachim Wolf Epstein-Barr virus sequences encoding a diagnostically relevant virus capsid antigen, expression clones derived through polymerase chain reaction and the use of this recombinant antigen in diagnostic tests
WO1995003415A3 (fr) * 1993-07-23 1995-03-16 Hans Joachim Wolf Sequences d'adn du virus epstein-barr codant un antigene de capside viral utilisable en diagnostic, clones d'expression derives par amplification pcr, et utilisation de cet antigene recombine dans des tests diagnostiques
WO1995003415A2 (fr) * 1993-07-23 1995-02-02 Hans Joachim Wolf Sequences d'adn du virus epstein-barr codant un antigene de capside viral utilisable en diagnostic, clones d'expression derives par amplification pcr, et utilisation de cet antigene recombine dans des tests diagnostiques
WO1996025909A2 (fr) * 1995-02-17 1996-08-29 Instituto De Salud Carlos Iii Procedes d'amplification de genomes et melanges d'oligonucleotides initiateurs pour la detection et l'identification d'agents infectieux apparentes
WO1996025909A3 (fr) * 1995-02-17 1996-09-26 Inst De Salud Carlos Iii Procedes d'amplification de genomes et melanges d'oligonucleotides initiateurs pour la detection et l'identification d'agents infectieux apparentes
ES2093554A1 (es) * 1995-02-17 1996-12-16 Inst De Salud Carlos Iii Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.
GB2301888A (en) * 1995-02-17 1996-12-18 Inst De Salud Carlos Iii Process for the genome amplification and mixtures of inducer oligonucleotides for the detection and identification of related infectious agents
EP1659187A1 (fr) * 2004-11-18 2006-05-24 bioMerieux B.V. Séquences d'acides nucléiques qui peuvent être utilisées comme amorces et sondes dans l'amplification et la détection de l'ADN de HSV et méthodes pour l'amplification et la détection de l'ADN de HSV en utilisant une amplification basée sur la transcription
WO2006053779A2 (fr) * 2004-11-18 2006-05-26 Biomerieux B.V. Sequences d'acides nucleiques qui peuvent etre utilisees comme amorces et sondes dans l'amplification et la detection de l'adn du hsv et procede pour l'amplification et la detection d'un adn du hsv au moyen d'une amplification fondee sur la transcription
WO2006053779A3 (fr) * 2004-11-18 2006-08-03 Biomerieux Bv Sequences d'acides nucleiques qui peuvent etre utilisees comme amorces et sondes dans l'amplification et la detection de l'adn du hsv et procede pour l'amplification et la detection d'un adn du hsv au moyen d'une amplification fondee sur la transcription
US8298761B2 (en) 2004-11-18 2012-10-30 Biomerieux B.V. Nucleic acid sequences that can be used as primers and probes in the amplification and detection of HSV DNA and method for the amplification and detection of HSV DNA using a transcription based amplification

Also Published As

Publication number Publication date
AU6164890A (en) 1991-03-11

Similar Documents

Publication Publication Date Title
US6238866B1 (en) Detector for nucleic acid typing and methods of using the same
JP2651483B2 (ja) ポリメラーゼ連鎖反応によるヒト乳頭腫ウイルスの検出
US6200747B1 (en) Method and kits for detection of fragile X specific, GC-rich DNA sequences
CA2239896C (fr) Procede d'evaluation de sequences genetiques polymorphes et leur utilisation pour identifier les types hla
US5389512A (en) Method for determining the relative amount of a viral nucleic acid segment in a sample by the polymerase chain reaction
AU724531B2 (en) Multiplex amplification of short tandem repeat loci
US5106727A (en) Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
EP0359789B1 (fr) Amplification et detection de sequences d'acides nucleiques
US5079351A (en) Oligonucleotides and kits for detection of htlvi and htlvii viruses by hybridization
EP0420260A2 (fr) ADN marqué de biotine par la réaction en chaîne de polymérase et de son dépistage
JP2802125B2 (ja) 核酸の検出方法
JPH02303489A (ja) ランダム配列のオリゴヌクレオチドをプライマーとして用いた核酸配列の増幅
WO2005085476A1 (fr) Detection d'un strp, tel que le syndrome de l'x fragile
EP0777747A1 (fr) Procede de sequen age de nucleotides
CA2004326A1 (fr) Essai de sequences utilisant des genes amplifies
WO2000009751A1 (fr) Methodes diagnostiques dans lesquelles l'essai en serie de loci polymorphes est utilise
US6063567A (en) Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
WO1991002091A1 (fr) Procede d'identification d'herpes virus et oligonucleotides utilises dans le procede
JP2002510962A (ja) 男性不妊ｙ欠失検出器具
Sjöroos et al. Time-resolved fluorometry based sandwich hybridisation assay for HLA-DQA1 typing
CN111593115A (zh) 用于β-地中海贫血基因突变多重实时荧光PCR检测的引物和探针组合及试剂盒
EP3458603A1 (fr) Polymorphismes penta e pour identification humaine
EP0819766A1 (fr) Polynucleotides permettant de deceler des leishmanies et procede de detection du protozoaire de la leishmanie
KR100247215B1 (ko) 신규한 non-a, non-b, non-c, non-d, non-e 간염 바이러스의 핵 산증폭 및 검출
WO2000011215A2 (fr) Procede de depistage diagnostique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA